EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug-induced kidney injury: challenges and opportunities

Skylar Connor iD, Ruth A Roberts iD, Weida Tong iD

Toxicology Research · 01.07.2024 · 13 (4)

DOI: 10.1093/toxres/tfae119 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicology Research, online erschienen am 05.08.2024. Verfasst von Skylar Connor und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, United States. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Toxicological Research, Oak Ridge Institute for Science and Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced kidney injury (DIKI) is a frequently reported adverse event, associated with acute kidney injury, chronic kidney disease, and end-stage renal failure. Prospective cohort studies on acute injuries suggest a frequency of around 14%–26% in adult populations and a significant concern in pediatrics with a frequency of 16% being attributed to a drug. In drug discovery and development, renal injury accounts for 8 and 9% of preclinical and clinical failures, respectively, impacting multiple therapeutic areas. Currently, the standard biomarkers for identifying DIKI are serum creatinine and blood urea nitrogen. However, both markers lack the sensitivity and specificity to detect nephrotoxicity prior to a significant loss of renal function. Consequently, there is a pressing need for the development of alternative methods to reliably predict drug-induced kidney injury (DIKI) in early drug discovery. In this article, we discuss various aspects of DIKI and how it is assessed in preclinical models and in the clinical setting, including the challenges posed by translating animal data to humans. We then examine the urinary biomarkers accepted by both the US Food and Drug Administration (FDA) and the European Medicines Agency for monitoring DIKI in preclinical studies and on a case-by-case basis in clinical trials. We also review new approach methodologies (NAMs) and how they may assist in developing novel biomarkers for DIKI that can be used earlier in drug discovery and development.

Schlagwörter

Stichwörter der Autor:innen

DIKIdrug discoverykidney injurynephrotoxicityrenal injury

Autor:innen und Institutionen

  • National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, United States.
  • ApconiX Ltd, Alderley Park, Alderley Edge, SK10 4TG, United Kingdom.
  • University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.

ORCID-Profile: Skylar Connor, Ruth A Roberts, Weida Tong

Förderung

  • National Center for Toxicological Research
  • Oak Ridge Institute for Science and Education

Zitieren

APA

Connor, S., Roberts, R. A., & Tong, W. (2024). Drug-induced kidney injury: challenges and opportunities. Toxicology Research, 13(4). https://doi.org/10.1093/toxres/tfae119

Vancouver

Connor S, Roberts RA, Tong W. Drug-induced kidney injury: challenges and opportunities. Toxicology Research. 2024;13(4). doi:10.1093/toxres/tfae119

BibTeX
@article{Connor2024,
  author = {Connor, Skylar and Roberts, Ruth A and Tong, Weida},
  title = {Drug-induced kidney injury: challenges and opportunities},
  journal = {Toxicology Research},
  year = {2024},
  volume = {13},
  number = {4},
  doi = {10.1093/toxres/tfae119}
}
Kostenlos starten →